Rehovot, Israel, May 1, 2013 – Evogene Ltd. (TASE: EVGN), a leading developer of improved plant traits for the food, feed and biofuel industries, announced today the appointment of Ms. Sigal Fattal as the Company’s Chief Financial Officer (CFO) effective May 1, 2013.
Ms. Fattal has been serving as the Company’s Vice President of Finance since her appointment for the role in October 2012. In her new role, Ms. Fattal will hold expanded responsibilities, overseeing corporate finance, legal counsel, operations and purchasing, administration and human resources. She will remain a member of the Company’s Executive Team.
Ms. Fattal joined Evogene in June 2012, serving as advisor to the Company’s Chief Executive Officer (CEO) on corporate matters, and was appointed as Vice President of Finance later that year. Prior to joining Evogene, she held executive accounting and finance positions in the financial sector, mainly with Blue Chip companies, including as CEO of wwCFO Ltd, and as CFO of Cal International, one of Israel’s largest credit card companies. Ms. Fattal holds a Bachelor degree in Accounting and Economics, which she completed with honors, and a Master degree in Business, both from Tel Aviv University.
“I am delighted to appoint Sigal for the role of CFO. The appointment credits her significant contribution to Evogene’s financial operations and executive team, and marks the Company’s ongoing growth and expanding operations,” said Ofer Haviv, Evogene’s President and CEO. “I am confident in her leadership and dedication as she takes on her extended responsibilities overseeing a core aspect of Evogene’s corporate operations.”
Evogene is a world leading discoverer and developer of improved plant traits through the use of integrated plant genomics. Combining proprietary state-of-the-art computational genomic technologies with advanced breeding methods, the company’s infrastructure provides a complete solution for plant trait improvement to its four market focused operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and seed development. In addition to its internal programs, Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene, listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN), is headquartered in Israel, with field operations in South America. For additional information, please visit Evogene’s website at www.evogene.com.
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene’s control, including, without limitation, those risk factors contained in Evogene’s reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Karen Mazor, Director
Public and Investor Relations